24 HR lamotrigine 50 MG Extended Release Oral Tablet
1 INDICATIONS AND USAGE Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 ) 1.1 Adjunctive Therapy Lamotrigine extended-release tablets USP are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. 1.2 Monotherapy Lamotrigine extended-release tablets USP are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Safety and effectiveness of lamotrigine extended-release tablets USP have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.3 Limitation of Use Safety and effectiveness of lamotrigine extended-release tablets for use in patients younger than 13 years have not been established.
Torrent Pharmaceuticals Limited
ROUND GREEN 340 50
Related Pills
24 HR lamotrigine 100 MG Extended Release Oral Tablet
Torrent Pharmaceuticals Limited
24 HR lamotrigine 25 MG Extended Release Oral Tablet
Torrent Pharmaceuticals Limited
lamotrigine tablet extended release
torrent pharmaceuticals limited
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
LAMOTRIGINE extended-release tablets , USP 25 mg, light yellow to yellow colored, round, biconvex, film coated tablets, debossed with '339' on one side and '25' on other side. Bottles of 30 NDC 13668-339-30 50 mg, light green to green colored, round, biconvex, film coated tablets, debossed with '340' on one side and '50' on other side. Bottles of 30 NDC 13668-340-30 100 mg, light orange to orange colored, round, biconvex, film coated tablets, debossed with '341' on one side and '100' on other side. Bottles of 30 NDC 13668-341-30 200 mg, light blue to blue colored, round, biconvex, film coated tablets, debossed with '342' on one side and '200' on other side. Bottles of 30 NDC 13668-342-30 Storage: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
More pills like ROUND 340 50